Antivascular Therapy for Epithelial Ovarian Cancer

Table 2

Ongoing trials with multitargeted tyrosine kinase inhibitors in ovarian cancer.

Agent	Targets	Phase	Intervention	Stage of the disease	Trial number
Sunitinib	VEGFRPDGFRc-kitRETCSF-1Rflt-3	II	Sunitinib monotherapy	Platinum-resistant recurrent	AGO-OVAR 2.11
					NCT00543049
					(Germany)
		II	Sunitinib monotherapy	Recurrent or refractory	DF08-056
					NCT00768144
					(United States)
		II	Sunitinib monotherapy	Advanced and/or metastatic	CAN-NCIC-IND185
					NCT00388037
					(Canada)
Sorafenib	Raf-1VEGFRPDGFRBflt-3c-kit	II	Sorafenib maintenance versus placebo	CR after standard platinum therapy	NCT00791778
		II	Paclitaxel and carboplatin +/− sorafenib	1st line	SCRI GYN 19NCT00390611
		II	Paclitaxel and carboplatin +/− sorafenib	Platinum-sensitive recurrent	CASE-CWRU-2804NCT00096200
		II	Topotecan + sorafenib	Platinum-resistant recurrent	GYN06-111NCT00526799
Pazopanib	VEGFRPDGFRc-kit	III	Pazopanib maintenance versus placebo	After 1st line chemo	AGO-OVAR16NCT00866697
		II	Pazopanib monotherapy	Recurrent	VEG104450NCT00281632
		I	Metronomic topotecan + pazopanib	Persistent or recurrent	NCT00800345
XL999	VEGFRPDGFRFGFRflt-3Src	II	XL999 monotherapy	Recurrent	NCT00277290
Motesanib	VEGFRPDGFRc-kit	II	Motesanib monotherapy	Persistent or recurrent	NCT00574951
Vandetanib	VEGFREGFR	II	Docetaxel +/−vandetanib	Persistent or recurrent	SWOG-S0904NCT00872989
		I/II	Pegliposomal doxorubicin +/− vandetanib	Platinum-refractory recurrent	NCT00862836

Studies were accessed from http://www.clinicaltrials.gov/ on May 17, 2009
VEGFR = vascular endothelial growth factor receptor, PDGFR = platelet-derived growth factor receptor,